Trial · NCT01877915
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke | Rivaroxaban | 13.44 | Event rate per 100 patient-year | ||
| Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke | Placebo | 14.27 | Event rate per 100 patient-year | ||
| Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF) | Rivaroxaban | 23.32 | Event rate per 100 patient-year | ||
| Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF) | Placebo | 23.46 | Event rate per 100 patient-year | ||
| Event Rate of Cardio Vascular Death | Rivaroxaban | 9.46 | Event rate per 100 patient-year | ||
| Event Rate of Cardio Vascular Death | Placebo | 9.96 | Event rate per 100 patient-year | ||
| Event Rate of Re-Hospitalization for Worsening of Heart Failure | Rivaroxaban | 17.24 | Event rate per 100 patient-year | ||
| Event Rate of Re-Hospitalization for Worsening of Heart Failure | Placebo | 17.45 | Event rate per 100 patient-year | ||
| Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV) | Rivaroxaban | 13.30 | Event rate per 100 patient-year | ||
| Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV) | Placebo | 14.04 | Event rate per 100 patient-year | ||
| Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure | Rivaroxaban | 24.84 | Event rate per 100 patient-year | ||
| Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure | Placebo | 24.57 | Event rate per 100 patient-year | ||
| Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability | Rivaroxaban | Fatal Bleeding | 0.22 | Event rate per 100 patient-year | |
| Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability | Placebo | Fatal Bleeding | 0.22 | Event rate per 100 patient-year | |
| Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability | Rivaroxaban | Critical Space Bleeding with Permanent Disability | 0.32 | Event rate per 100 patient-year | |
| Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability | Placebo | Critical Space Bleeding with Permanent Disability | 0.48 | Event rate per 100 patient-year | |
| Event Rate of Bleeding Events That Requiring Hospitalization | Rivaroxaban | 1.52 | Event rate per 100 patient-year | ||
| Event Rate of Bleeding Events That Requiring Hospitalization | Placebo | 1.16 | Event rate per 100 patient-year | ||
| Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event | Rivaroxaban | 2.04 | Event rate per 100 patient-year | ||
| Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event | Placebo | 1.21 | Event rate per 100 patient-year |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01877915/results